CellaVision AB (publ)
CellaVision AB (publ) (CLVSF) Financial Performance & Income Statement Overview
Explore the financials of CellaVision AB (publ) (CLVSF), including yearly and quarterly data on income, cash flow, and balance sheets.
CellaVision AB (publ) (CLVSF) Income Statement & Financial Overview
View the income breakdown for CellaVision AB (publ) CLVSF across both annual and quarterly reports.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $194.80M | $186.69M | $178.66M | $187.79M |
| Cost of Revenue | $57.59M | $57.52M | $57.37M | $63.24M |
| Gross Profit | $137.21M | $129.17M | $121.29M | $124.55M |
| Gross Profit Ratio | $0.70 | $0.69 | $0.68 | $0.66 |
| R&D Expenses | $24.58M | $20.30M | $26.30M | $19.98M |
| SG&A Expenses | $55.51M | $57.52M | $56.59M | $55.45M |
| Operating Expenses | $80.09M | $77.82M | $82.89M | $75.44M |
| Total Costs & Expenses | -$137.68M | $135.34M | $140.26M | $138.68M |
| Interest Income | $610000.00 | $2.88M | $1.10M | $1.69M |
| Interest Expense | $0.00 | $2.74M | $582000.00 | $2.59M |
| Depreciation & Amortization | $9.34M | $7.59M | $10.38M | $10.59M |
| EBITDA | $67.07M | $61.82M | $49.88M | $57.71M |
| EBITDA Ratio | $0.34 | $0.33 | $0.28 | $0.31 |
| Operating Income | $57.12M | $51.35M | $38.40M | $49.11M |
| Operating Income Ratio | $0.29 | $0.28 | $0.21 | $0.26 |
| Other Income/Expenses (Net) | -$4.62M | $139000.00 | $521000.00 | -$904000.00 |
| Income Before Tax | $52.50M | $51.49M | $38.92M | $48.21M |
| Income Before Tax Ratio | $0.27 | $0.28 | $0.22 | $0.26 |
| Income Tax Expense | $10.98M | $10.55M | $7.80M | $9.66M |
| Net Income | $41.52M | $40.94M | $31.11M | $38.55M |
| Net Income Ratio | $0.21 | $0.22 | $0.17 | $0.21 |
| EPS | $1.74 | $1.72 | $1.30 | $1.62 |
| Diluted EPS | $1.74 | $1.72 | $1.30 | $1.62 |
| Weighted Avg Shares Outstanding | $23.85M | $23.85M | $23.85M | $23.85M |
| Weighted Avg Shares Outstanding (Diluted) | $23.85M | $23.85M | $23.85M | $23.85M |
Financial performance has remained strong, with revenue growing from $187.79M in Q2 2024 to $194.80M in Q1 2025. Gross profit continued to perform well, with margins at 70% in the latest quarter. Operating income reached $57.12M in Q1 2025, holding a steady 29% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $67.07M. Net income rose to $41.52M, keeping EPS at $1.74. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan